Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions

Stem Cell Rev Rep. 2021 Jun;17(3):862-877. doi: 10.1007/s12015-020-10091-w. Epub 2020 Nov 23.

Abstract

Tissue engineered vascular grafts (TEVGs) generated from human primary cells represent a promising vascular interventional therapy. However, generation and application of these TEVGs may be significantly hindered by the limited accessibility, finite expandability, donor-donor functional variation and immune-incompatibility of primary seed cells from donors. Alternatively, human induced pluripotent stem cells (hiPSCs) offer an infinite source to obtain functional vascular cells in large quantity and comparable quality for TEVG construction. To date, TEVGs (hiPSC-TEVGs) with significant mechanical strength and implantability have been generated using hiPSC-derived seed cells. Despite being in its incipient stage, this emerging field of hiPSC-TEVG research has achieved significant progress and presented promising future potential. Meanwhile, a series of challenges pertaining hiPSC differentiation, vascular tissue engineering technologies and future production and application await to be addressed. Herein, we have composed this review to introduce progress in TEVG generation using hiPSCs, summarize the current major challenges, and encapsulate the future directions of research on hiPSC-based TEVGs. Graphical abstract.

Keywords: Endothelial cell; Human induced pluripotent stem cell; Smooth muscle cell; Tissue engineered vascular graft; Tissue engineering.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Blood Vessel Prosthesis
  • Humans
  • Induced Pluripotent Stem Cells*